FDA deals ISTA a blow

Article

ISTA Pharmaceuticals has received a not approvable letter from the FDA relating to its New Drug Application (NDA) for T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension).

ISTA Pharmaceuticals has received a not approvable letter from the FDA relating to its New Drug Application (NDA) for T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension).

T-Pred is a topical steroid developed for the treatment of inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial ocular infections or a risk of bacterial infection exists.

A multicentre, randomized, double-blind study was conducted to determine bioequivalence of prednisolone concentrations between T-Pred and PredForte (prednisolone acetate 1.0%). ISTA believes that the study achieved or exceeded the goal, both in the intent-to-treat and the per-protocol patient populations. Furthermore, the company also believes that the study shows T-Pred to have antimicrobial activity equivalent to other combination products approved for this indication.

However, FDA assessment of the clinical data did not show sufficient equivalence between the prednisolone component in T-Pred and PredForte. ISTA disagrees with the findings and plans to request a meeting with the FDA as soon as possible to discuss the matter.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.